{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:34:43Z","timestamp":1788536083869,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","award":["625-166-2025"],"award-info":[{"award-number":["625-166-2025"]}],"id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015063","name":"National Institute of Technology Calicut","doi-asserted-by":"publisher","award":["2024-25"],"award-info":[{"award-number":["2024-25"]}],"id":[{"id":"10.13039\/501100015063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["EEQ\/2020\/000303"],"award-info":[{"award-number":["EEQ\/2020\/000303"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SR\/FIST\/CS-I\/2019\/ 120"],"award-info":[{"award-number":["SR\/FIST\/CS-I\/2019\/ 120"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004541","name":"Ministry of Education, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmc.2025.118352","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:14:41Z","timestamp":1755620081000},"page":"118352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Identification of pyrazole-acrylonitrile derivatives as potential anticancer agents and mechanistic insights"],"prefix":"10.1016","volume":"130","author":[{"given":"K.","family":"Fabitha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munugala","family":"Chandrakanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Kallingal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Maciejewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Telukuntla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Gondru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjith","family":"Kumavath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.D.","family":"Demina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janardhan","family":"Banothu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118352_bb0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1039\/C6NJ03181A","article-title":"Shamsuzzaman, review: biologically active pyrazole derivatives","volume":"41","author":"Ansari","year":"2017","journal-title":"New J Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejmech.2013.10.004","article-title":"Pyrazole scaffold: a remarkable tool in the development of anticancer agents","volume":"70","author":"Kumar","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0015","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1016\/j.bmc.2017.09.035","article-title":"Recently reported biological activities of pyrazole compounds","volume":"25","author":"Faria","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103470","article-title":"Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line","volume":"97","author":"Bennani","year":"2020","journal-title":"Bioorg Chem"},{"issue":"2022","key":"10.1016\/j.bmc.2025.118352_bb0025","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1039\/D2MD00206J","article-title":"Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies","volume":"13","author":"Li","year":"2022","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0030","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1021\/jm00075a014","article-title":"Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates","volume":"36","author":"Ashton","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14656566.2019.1645123","article-title":"Celecoxib for the treatment of musculoskeletal arthritis","volume":"20","author":"Krasselt","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmc.2025.118352_bb0040","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40265-016-0644-6","article-title":"Apixaban: a review in venous thromboembolism","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2025.118352_bb0045","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s13738-020-01873-7","article-title":"Synthesis and anti-rotavirus activity of some nitrogen heterocycles integrated with pyrazole scaffold","volume":"17","author":"El-Helw","year":"2020","journal-title":"J Iran Chem Soc"},{"key":"10.1016\/j.bmc.2025.118352_bb0050","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.physbeh.2007.11.012","article-title":"Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome","volume":"93","author":"Vemuri","year":"2008","journal-title":"Physiol Behav"},{"key":"10.1016\/j.bmc.2025.118352_bb0055","first-page":"21","article-title":"Chapter 3 antidepressant agents","volume":"22","author":"Luttinger","year":"1987","journal-title":"Annu Rep Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/bcp.12824","article-title":"Antidotes for poisoning by alcohols that form toxic metabolites","volume":"81","author":"McMartin","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2025.118352_bb0065","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nrd3600","article-title":"Crizotinib","volume":"10","author":"Shaw","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118352_bb0070","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of Crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transitionfactor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0075","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1186\/1744-8069-6-87","article-title":"Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain","volume":"6","author":"Ghilardi","year":"2010","journal-title":"Mol Pain"},{"key":"10.1016\/j.bmc.2025.118352_bb0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2025.118352_bb0085","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","article-title":"An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomyosin-related kinase (TRK) inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2025.118352_bb0090","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1021\/jm0408870","article-title":"3-Aminopyrazole inhibitors of CDK2\/cyclin a as antitumor agents. 2. Lead optimization","volume":"48","author":"Pevarello","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/13543784.2012.652303","article-title":"Danusertib, an aurora kinase inhibitor","volume":"21","author":"Meulenbeld","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmc.2025.118352_bb0100","doi-asserted-by":"crossref","first-page":"21805","DOI":"10.3390\/ijms141121805","article-title":"New potential antitumor pyrazole derivatives: synthesis and cytotoxic evaluation","volume":"14","author":"Nitulescu","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118352_bb0105","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.clml.2013.09.006","article-title":"Ruxolitinib for myelofibrosis - an update of its clinical effects","volume":"13","author":"Kantarjian","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bmc.2025.118352_bb0110","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1016\/j.bmc.2013.07.016","article-title":"Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity","volume":"21","author":"Baviskar","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0115","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1021\/jm051247f","article-title":"Synthesis and antitumor characterization of pyrazolic analogues of the marine pyrroloquinoline alkaloids: Wakayin and tsitsikammamines","volume":"49","author":"Legentil","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0120","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1021\/jm200235u","article-title":"N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase II\u03b1 and induce apoptosis in G1\/S phase","volume":"54","author":"Baviskar","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0125","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bmcl.2015.11.040","article-title":"Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR\/HER-2 kinase inhibitors","volume":"26","author":"Tao","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118352_bb0130","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bmcl.2007.12.035","article-title":"Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors","volume":"18","author":"Ducray","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118352_bb0135","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.bmc.2013.01.074","article-title":"Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor","volume":"21","author":"Miyamoto","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0140","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0145","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1016\/j.bmcl.2010.08.067","article-title":"Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase","volume":"20","author":"Staben","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118352_bb0150","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejmech.2016.01.013","article-title":"Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1 H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy","volume":"109","author":"Wen","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0155","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ejmech.2014.09.024","article-title":"Design, synthesis, and biological evaluation of 1, 3-disubstituted- pyrazole derivatives as new class I and IIb histone deacetylase inhibitors","volume":"86","author":"Yao","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0160","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejmech.2014.12.053","article-title":"Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor","volume":"92","author":"Aware","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0165","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","volume":"55","author":"Cui","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0170","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejmech.2013.10.077","article-title":"Design and synthesis of pyrazole-oxindole conjugates targeting tubulin polymerization as new anticancer agents","volume":"92","author":"Kamal","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejmech.2014.04.051","article-title":"Synthesis of 5-substituted-1H-pyrazolo[4,3- d]pyrimidin-7(6H)-one analogs and their biological evaluation as anticancer agents: mTOR inhibitors","volume":"80","author":"Reddy","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0180","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1016\/j.bmc.2014.08.029","article-title":"Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors","volume":"22","author":"Wang","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0185","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bmc.2014.11.029","article-title":"Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF (V600E) inhibitors","volume":"23","author":"Zhao","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0190","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1016\/j.bmc.2014.06.020","article-title":"Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors","volume":"22","author":"Park","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2013.07.003","article-title":"Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors","volume":"68","author":"Sun","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0200","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/acsmedchemlett.5b00226","article-title":"Discovery of a highly selective JAK2 inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms","volume":"6","author":"Wan","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118352_bb0205","doi-asserted-by":"crossref","first-page":"9242","DOI":"10.1021\/jm401333u","article-title":"Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach","volume":"56","author":"Frank","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0210","doi-asserted-by":"crossref","first-page":"12724","DOI":"10.3390\/ijms241612724","article-title":"Xu recent advances in the development of Pyrazole derivatives as anticancer agents","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118352_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102929","article-title":"Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers","volume":"88","author":"Metwally","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202201064","article-title":"Recent developments in the synthesis of indole-pyrazole hybrids","volume":"7","author":"Fabitha","year":"2022","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bmc.2025.118352_bb0225","doi-asserted-by":"crossref","first-page":"22486","DOI":"10.1038\/s41598-023-48494-7","article-title":"Novel 3-(pyrazol-4-yl)-2-(1H-indole-3-carbonyl)acrylonitrile derivatives induce intrinsic and extrinsic apoptotic death mediated P53 in HCT116 colon carcinoma","volume":"13","author":"Mohamed","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118352_bb0230","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1021\/acsomega.0c00630","article-title":"Molecular hybrids integrated with benzimidazole and pyrazole structural motifs: design, synthesis, biological evaluation, and molecular docking studies","volume":"5","author":"Sivaramakarthikeyan","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2025.118352_bb0235","article-title":"1,2,3-Triazole\u2013[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine hybrids: a switch for improvement of antibreast cancer activity targeting epidermal growth factor receptor","volume":"146","author":"Praveen","year":"2024","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2025.118352_bb0240","doi-asserted-by":"crossref","first-page":"8038","DOI":"10.1039\/D4NJ00824C","article-title":"Novel fused pyran derivatives induce apoptosis and target cell cycle progression in anticancer efficacy against multiple cell lines","volume":"48","author":"Fabitha","year":"2024","journal-title":"New J Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.137197","article-title":"Coumarin\u20131,2,4-triazole hybrids: recent advances in synthesis and medicinal applications","volume":"1299","author":"Chandrakanth","year":"2024","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2025.118352_bb0250","article-title":"Coumarin\u2013benzimidazole hybrids: a review of developments in medicinal chemistry","volume":"227","author":"Arya","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118352_bb0255","article-title":"Synthesis, anticancer and antibacterial evaluation of novel 1,3-disubstituted-1H-pyrazole-4-yl-methylene embedded fused thiazolo[2,3-b]quinazolinones","volume":"30","author":"Rajitha","year":"2020","journal-title":"Chem Data Coll"},{"key":"10.1016\/j.bmc.2025.118352_bb0260","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bmcl.2014.10.100","article-title":"One-pot multicomponent synthesis of indole incorporated thiazolylcoumarins and their antibacterial, anticancer and DNA cleavage studies","volume":"25","author":"Gali","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118352_bb0265","doi-asserted-by":"crossref","first-page":"22866","DOI":"10.1039\/c4ra02514h","article-title":"Synthesis, characterization and biological evaluation of fused thiazolo[3,2-a]pyrimidine derivatives","volume":"4","author":"Banothu","year":"2014","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2025.118352_bb0270","doi-asserted-by":"crossref","first-page":"53812","DOI":"10.1039\/C4RA11428K","article-title":"Synthesis and in vitro cytotoxic activity of novel coumarinylimidazo[2,1-b]thiazole derivatives","volume":"4","author":"Gali","year":"2014","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2025.118352_bb0275","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1016\/j.bmcl.2014.07.030","article-title":"Indolylmethylene benzo[h]thiazolo[2,3-b]quinazolinones: synthesis, characterization and evaluation of anticancer and antimicrobial activities","volume":"24","author":"Gali","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118352_bb0280","unstructured":"H. Mitchell, M.E. Fraley, A.J. Cooke, et al. TrkA kinase inhibitors, compositions and methods thereof, patent no. WO 2015\/143653 Al."},{"key":"10.1016\/j.bmc.2025.118352_bb0285","series-title":"An Investigation into the Use of Computational and In Vitro Methods for Acute Systemic Toxicity Prediction","first-page":"10","author":"Norl\u00e9n","year":"2012"},{"key":"10.1016\/j.bmc.2025.118352_bb0290","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jhet.4488","article-title":"Novel tryptanthrin hybrids bearing aminothiazoles as potential EGFR inhibitors: design, synthesis, biological screening, molecular docking studies, and ADME\/T predictions","volume":"59","author":"Rambabu","year":"2022","journal-title":"J Heterocyclic Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:57:25Z","timestamp":1762347445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625002937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":58,"alternative-id":["S0968089625002937"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118352","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of pyrazole-acrylonitrile derivatives as potential anticancer agents and mechanistic insights","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118352"}}